Table 5.
Treatment During Hospitalization and at Discharge According to Thrombosis Site.
| Treatment | CVT, n = 25 | JVT, n = 16 | UEDVT, n = 33 | AVT, n = 33 |
|---|---|---|---|---|
| During hospitalization | ||||
| LMWH, n (%) | 16 (64.0%) | 11 (68.8%) | 27 (81.8%) | 28 (84.8%) |
| UFH, n (%) | 5 (20.0%) | 2 (12.5%) | 1 (3.0%) | 1 (3.0%) |
| No treatment, n (%) | 4 (16.0%) | 3 (18.8%) | 5 (15.6%) | 4 (12.1%) |
| At discharge | ||||
| LMWH, n (%) | 14 (56.0%) | 14 (87.5%) | 26 (78.8%) | 25 (75.8%) |
| AVK, n (%) | 8 (32.0%) | 1 (6.2%) | 1 (3.0%) | 3 (9.1%) |
| DOAC, n (%) | 1 (4.0%) | 0 (0.0%) | 3 (9.1%) | 3 (9.1%) |
| No treatment, n (%) | 2 (8.0%) | 1 (6.2%) | 3 (9.1%) | 2 (6.1%) |
Abbreviations: AVK, antivitamin K; AVT, abdominal vein thrombosis; CVT, cerebral vein thrombosis; DOAC, direct oral anticoagulants; JVT, jugular vein thrombosis; LMWH, low-molecular-weight heparin; UEDVT, upper extremities deep vein thrombosis; UFH, unfractionated heparin.